FASN and Hepatic steatosis: Our data demonstrate that FASstatin decreased FASN protein expression (Figure 9L) and significantly reduced body and liver weights (Figure 9M), hepatic steatosis, fibrosis, and inflammation, and serum ALT and AST activity (Figure 9, N and O).